Zevra Denmark A/S - CVR: 43259326

2023, DKK

17.07.2024

Bruttoresultat

-12.548'

Primær drift

-28.188'

Årets resultat

-20.506'

Aktiver

189''

Kortfristede aktiver

66.170'

Egenkapital

-27.513'

Afkastningsgrad

-15 %

Soliditetsgrad

-15 %

Likviditetsgrad

40 %

Resultat

17.07.2024

Årsrapport	2023 17.07.2024	2022 24.07.2023
Nettoomsætning
Bruttoresultat	-12.548.000	1.671.000
Resultat af primær drift	-28.188.000	-12.009.000
Indtægter af kapitalandele (tilknyttede og associerede)	0	0
Finansielle indtægter	1.596.000	29.000
Finansieringsomkostninger	-10.000	0
Andre finansielle omkostninger	0	0
Resultat før skat	-26.602.000	-11.980.000
Resultat	-20.506.000	-7.406.000
Forslag til udbytte	0	0

Aktiver

17.07.2024

Årsrapport	2023 17.07.2024	2022 24.07.2023
Kortfristede varebeholdninger	3.021.000	4.679.000
Kortfristede tilgodehavender fra salg og tjenesteydelser	38.695.000	0
Likvider	24.454.000	19.199.000
Kortfristede aktiver	66.170.000	75.689.000
Immaterielle aktiver og goodwill	122.419.000	0
Finansielle anlægsaktiver	259.000	0
Materielle aktiver	298.000	595.000
Langfristede aktiver	122.976.000	123.517.000
Aktiver	189.146.000	199.206.000

Aktiver

17.07.2024

Passiver

17.07.2024

Årsrapport	2023 17.07.2024	2022 24.07.2023
Forslag til udbytte	0	0
Egenkapital	-27.513.000	-7.006
Hensatte forpligtelser	330.000	926.000
Langfristet gæld til banker	0	0
Leverandører af varer og tjenesteydelser	16.142.000	11.454.000
Kortfristede forpligtelser	164.659.000	175.118.000
Gældsforpligtelser	216.329.000	205.286.000
Forpligtelser	216.329.000	205.286.000
Passiver	189.146.000	199.206.000

Passiver

17.07.2024

Nøgletal

17.07.2024

Årsrapport	2023 17.07.2024	2022 24.07.2023
Afkastningsgrad	-14,9 %	-6,0 %
Dækningsgrad	Na.	Na.
Resultatgrad	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.
Egenkapitals-forretning	74,5 %	105.709,4 %
Payout-ratio	Na.	Na.
Gældsdæknings-nøgletal	-281.880,0 %	Na.
Soliditestgrad	-14,5 %	0,0 %
Likviditetsgrad	40,2 %	43,2 %

Resultat

17.07.2024

Gæld

17.07.2024

Årsrapport

17.07.2024

Nyeste:01.01.2023- 31.12.2023(offentliggjort: 17.07.2024)

Information om virksomhedens regnskabsklasse:The annual report of Zevra Denmark A/S for 2023 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B and elective choice of certain provisions applying to reporting class C entities. The accounting policies applied are consistent with those of last year. The annual report for 2023 is presented in kDKK

Beretning

17.07.2024

Beskrivelse af usikkerhed ved indregning eller måling:Recognition and measurement uncertainties The Company's management has assessed that there are key accounting estimates related to impairment of the intangible assets relating to Arimoclomol asset in note 5 and estimations regarding revenue provisions (discount and rebate liabilities) on the liability side of the balance sheet to the financial statements in note 7.

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:The Board of directors and executive board have today discussed and approved the annual report of Zevra Denmark A/S for the financial year 1 January - 31 December 2023.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Business review Zevra Denmark A/S (the Company) is a subsidiary of Zevra Therapeutics, Inc. , a U. S.-based rare disease therapeutics company. Zevra Therapeutics, Inc. (Florida USA) became a public traded company on the NASDAQ Stock Exchange as of 7 January 2021. Zevra Denmark A/S is a rare disease therapeutics company leading with science to make life-changing therapeutics available to patients with significant unmet needs. The Company’s main asset includes arimoclomol, an orally-delivered investigational product candidate being developed for Niemann-Pick disease type C ("NPC"), which has been granted orphan drug designation, fast-track designation, breakthrough therapy designation and rare pediatric disease designation for the treatment of NPC by the U. S. Food and Drug Administration (FDA) and orphan medical product designation for the treatment of NPC by the European Medicines Agency (EMA). The Company changed its name from KemPharm Denmark A/S to Zevra Denmark A/S in 2023. Due to the Company being established on May 13, 2022, its income statement for the year 2022 covers a period of 7 months, as opposed to the full 12 months in 2023.